- Home
- IMRN vs SCNX Comparison
IMRN vs SCNX Comparison
Compare IMRN & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- SCNX
- Stock Information
- Founded
- IMRN 1994
- SCNX 2010
- Country
- IMRN Australia
- SCNX United States
- Employees
- IMRN N/A
- SCNX N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- IMRN Health Care
- SCNX Health Care
- Exchange
- IMRN Nasdaq
- SCNX Nasdaq
- Market Cap
- IMRN 14.4M
- SCNX 31.5M
- IPO Year
- IMRN N/A
- SCNX 2020
- Fundamental
- Price
- IMRN $1.64
- SCNX $0.74
- Analyst Decision
- IMRN
- SCNX
- Analyst Count
- IMRN 0
- SCNX 0
- Target Price
- IMRN N/A
- SCNX N/A
- AVG Volume (30 Days)
- IMRN 386.2K
- SCNX 64.4M
- Earning Date
- IMRN 08-29-2025
- SCNX 11-12-2025
- Dividend Yield
- IMRN N/A
- SCNX N/A
- EPS Growth
- IMRN N/A
- SCNX N/A
- EPS
- IMRN N/A
- SCNX N/A
- Revenue
- IMRN $4,777,422.00
- SCNX $128,202.00
- Revenue This Year
- IMRN N/A
- SCNX N/A
- Revenue Next Year
- IMRN N/A
- SCNX N/A
- P/E Ratio
- IMRN N/A
- SCNX N/A
- Revenue Growth
- IMRN 48.63
- SCNX N/A
- 52 Week Low
- IMRN $1.42
- SCNX $0.46
- 52 Week High
- IMRN $2.48
- SCNX $8.72
- Technical
- Relative Strength Index (RSI)
- IMRN 33.86
- SCNX 46.71
- Support Level
- IMRN $1.42
- SCNX $0.69
- Resistance Level
- IMRN $1.99
- SCNX $1.11
- Average True Range (ATR)
- IMRN 0.15
- SCNX 0.31
- MACD
- IMRN -0.08
- SCNX -0.02
- Stochastic Oscillator
- IMRN 22.58
- SCNX 13.31
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.